Form 4 Filing for BioStem Technologies, Inc.

This filing details transactions by Brandon Poe, Chief Financial Officer of BioStem Technologies, Inc. On September 15, 2026, Poe acquired 1694 shares of Common Stock through a non-derivative transaction with no cost. Concurrently, Poe disposed of 1694 Restricted Stock Units, which represent a contingent right to receive one share of the issuer's common stock. These units vest over three years from the grant date of September 15, 2024. Following these transactions, Poe holds 58062 shares of Common Stock and 6775 Restricted Stock Units. The filing also discloses holdings of stock options, with some vesting schedules detailed in footnotes. Specifically, options with an exercise price of $6.48 and expiration date of August 19, 2035, show 38814 shares owned, and options with an exercise price of $5.50 and expiration date of February 11, 2036, show 117401 shares owned. Additional Restricted Stock Units are held, with vesting schedules detailed in footnotes F5 and F6.